Research review on the pharmacological effects of astragaloside<scp>IV</scp>

Li, Lei; Hou, Xianguang; Rongfang, Xu; Liu, Chang; Tu, Menbayaer

doi:10.1111/fcp.12232

Cited by 278 publications

(185 citation statements)

References 178 publications

Supporting

Mentioning

181

Contrasting

Order By: Relevance

“…AS-IV has multiple pharmacologic effects for its potent anti-inflammatory, anti-fibrotic, anti-oxidative stress, anti-asthma, anti-diabetes and immune-regulatory effects [11]. In addition, AS-IV has been shown to exert anti-tumorigenic properties in certain cancers, including breast cancer and colorectal cancer [12,13].…”

Section: Introductionmentioning

confidence: 99%

Astragaloside IV Protects Rat Cardiomyocytes from Hypoxia-Induced Injury by Down-Regulation of miR-23a and miR-92a

Gong

Chang

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Astragaloside IV (AS-IV), a traditional Chinese medicine isolated from Astragalus membranaceus, has been shown to exert cardioprotective effect previously. This study aimed to reveal the effects of AS-IV on hypoxia-injured cardiomyocyte. Methods: H9c2 cells were treated with various doses of AS-IV for 24 h upon hypoxia. CCK-8 assay, flow cytometry/Western blot, and qRT-PCR were respectively conducted to measure the changes in cell viability, apoptosis, and the expression of miR-23a and miR-92a. Sprague–Dawley rats were received coronary ligation, and were administrated by various doses of AS-IV for 14 days. The infarct volume and outcome of rats followed by ligation were tested by ultrasound, arteriopuncture and nitrotetrazolium blue chloride (NBT) staining. Results: We found that 10 μg/ml of AS-IV exerted myocardioprotective effects against hypoxia-induced cell damage, as AS-IV significantly increased H9c2 cells viability and decreased apoptosis. Interestingly, the myocardioprotective effects of AS-IV were alleviated by miR-23a and/or miR-92a overexpression. Knockdown of miR-23a and miR-92a activated PI3K/AKT and MAPK/ ERK signaling pathways. Bcl-2 was a target gene for miR-23a, and BCL2L2 was a target gene for miR-92a. In the animal model of myocardial infarction (MI), AS-IV significantly reduced the infarct volume, ejection fraction (EF), shortening fraction (FS) and LV systolic pressure (LVSP), and significantly increased left ventricular end-diastolic internal diameter (LVEDd). And also, the elevated expression of miR-23a and miR-92a in MI rat was reduced by AS-IV. Conclusion: AS-IV protected cardiomyocytes against hypoxia-induced injury possibly via down-regulation of miR-23a and miR-92a, and via activation of PI3K/AKT and MAPK/ERK signaling pathways.

show abstract

Section: Introductionmentioning

confidence: 99%

Astragaloside IV Protects Rat Cardiomyocytes from Hypoxia-Induced Injury by Down-Regulation of miR-23a and miR-92a

Gong

Chang

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…130 Astragalus membranaceus contains a variety of substances, including saponin, polysaccharide, and flavonoid, that have been reported to have anti-inflammatory, antioxidative stress, immunoregulation, and cardioprotective effects via numerous signaling pathways in vital organs and systems. 131 The efficacy of Astragalus membranaceus for treating PSF is being assessed in an ongoing randomized, placebo-controlled, double-blind trial. 130 To sum up, there are a number of promising pharmacological agents for PSF.…”

Section: Pharmacological Interventionmentioning

confidence: 99%

Poststroke Fatigue: Emerging Evidence and Approaches to Management: A Scientific Statement for Healthcare Professionals From the American Heart Association

Hinkle¹,

Becker²,

Kim³

et al. 2017

Stroke

142

129

View full text Add to dashboard Cite

At least half of all stroke survivors experience fatigue; thus, it is a common cause of concern for patients, caregivers, and clinicians after stroke. This scientific statement provides an international perspective on the emerging evidence surrounding the incidence, prevalence, quality of life, and complex pathogenesis of poststroke fatigue. Evidence for pharmacological and nonpharmacological interventions for management are reviewed, as well as the effects of poststroke fatigue on both stroke survivors and caregivers.

show abstract

“…AST-IV served as a quality-control marker component of Huangqi in the Chinese Pharmacopoeia (2015 version). The previous studies have demonstrated that AST-IV possesses antioxidant, anti-inflammatory, and antiapoptotic effects on focal cerebral ischemia/reperfusion (I/R), cardiovascular disease, pulmonary disease, liver cirrhosis, and renal disease [6]. In the past decades, there have been a growing number of divergent preclinical researches examining the effects of AST-IV on focal cerebral ischemia in animal models [2].…”

Section: Introductionmentioning

confidence: 99%

Astragaloside IV for Experimental Focal Cerebral Ischemia: Preclinical Evidence and Possible Mechanisms

Wang

Zhou

et al. 2017

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Astragaloside IV (AST-IV) is a principal component of Radix Astragali seu Hedysari (Huangqi) and exerts potential neuroprotection in experimental ischemic stroke. Here, we systematically assessed the effectiveness and possible mechanisms of AST-IV for experimental acute ischemic stroke. An electronic search in eight databases was conducted from inception to March 2016. The study quality score was evaluated using the CAMARADES. Rev Man 5.0 software was used for data analyses. Thirteen studies with 244 animals were identified. The study quality score of included studies ranged from 3/10 to 8/10. Eleven studies showed significant effects of AST-IV for ameliorating the neurological function score (P < 0.05); seven studies for reducing the infarct volume (P < 0.05); and three or two studies for reducing the brain water content and Evans blue leakage (P < 0.05), respectively, compared with the control. The mechanisms of AST-IV for ischemic stroke are multiple such as antioxidative/nitration stress reaction, anti-inflammatory, and antiapoptosis. In conclusion, the findings of present study indicated that AST-IV could improve neurological deficits and infarct volume and reduce the blood-brain barrier permeability in experimental cerebral ischemia despite some methodological flaws. Thus, AST-IV exerted a possible neuroprotective effect during the cerebral ischemia/reperfusion injury largely through its antioxidant, anti-inflammatory, and antiapoptosis properties.

show abstract

Research review on the pharmacological effects of astragalosideIV

Cited by 278 publications

References 178 publications

Astragaloside IV Protects Rat Cardiomyocytes from Hypoxia-Induced Injury by Down-Regulation of miR-23a and miR-92a

Astragaloside IV Protects Rat Cardiomyocytes from Hypoxia-Induced Injury by Down-Regulation of miR-23a and miR-92a

Poststroke Fatigue: Emerging Evidence and Approaches to Management: A Scientific Statement for Healthcare Professionals From the American Heart Association

Astragaloside IV for Experimental Focal Cerebral Ischemia: Preclinical Evidence and Possible Mechanisms

Contact Info

Product

Resources

About